COVID-19 News
-
Showcase
Empatica partnering with U.S. Army MRDC to deploy COVID-19 early detection wearable
BOSTON, Nov. 6, 2020 /PRNewswire/ -- Empatica has been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to deploy a wearable and algorithm that enable the early and pre-symptomatic detection of COVID-19. The project's focus is on protecting the health of the general population by preventing outbreaks via early detection and alerting. Empatica's Aura algorithm gives a ...
-
Johnson & Johnson Institutes launches COVID-19 Community Hub
AIS with collaboration with Johnson & Johnson Institute has launched a special website dedicated to internal and external content to help healthcare workers keep up on the latest news on COVID-19. The site features: Webinars presented by physicians and leaders in the battle against COVID-19 The New Normal in Elective Surgery Thoracic Surgery on the Frontline of COVID-19 Managing ...
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
IONICON Analyzers at the Forefront of International COVID-19 Testing Research
A non-invasive test for COVID-19 with instant results would be a gamechanger in the efforts against COVID-19. Breath analysis shows a great potential for a rapid, non-invasive detection of COVID-19 infections. Follow our journey around the world, where we shine a light on current research projects where IONICON PTR-TOF instruments are deployed fighting this global pandemic by testing breath for ...
-
COVID-19
Elkton, Maryland- Micropore is proud to announce the continued support of portable ventilators manufactured by Thornhill Medical for the U.S. Marines, along with Canada’s civilian use for the COVID-19 Pandemic. On March 31, 2020, Canadian Prime Minister Justin Trudeau and Federal Minister of Innovation, Science, and Industry Navdeep Bains announced that Toronto-based Thornhill Medical, a ...
-
Covid-19 or Seasonal Allergy: How to differentiate?
COVID-19 and seasonal allergies have many of the same signs and symptoms. However, there are some differences, knowing them can help you seek out the right treatments to provide effective relief. Unlike COVID-19, seasonal allergies aren't caused by a virus. Seasonal allergies are immune system responses triggered by exposure to allergens, such as seasonal tree or grass pollens. To complicate ...
-
Coronavirus Resource Center
We understand concerns about COVID-19 (Novel Coronavirus) are top of mind for our members and the brewing community. Below is an evolving collection of resources to consider related to your brewery business. All Brewers Association-authored resources relating to COVID-19 have also been organized in the Resource Hub and are available to all for free so everyone has access to important ...
-
BioLingus to Develop a Sublingual Vaccine for COVID in Cooperation With the Korean CHA Vaccine Institute and PanGen Biotech
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
By BioLingus AG
-
Notitia Biotechnologies company announces expansion of study population for Covid-19 phase 2 study (COVGUT20) for NBT-NM108
After months of preparation, Notitia Biotechnologies Company (Notitia) announced that its COVID-19 Phase 2 study (COVGUT20) for NBT-NM108 has been given support by the Food and Drug Administration (FDA) to expand its study population to all symptomatic COVID-19 patients. "Previously, our trial focused on COVID-19 patients with type 2 diabetes and prediabetes. Now with this timely expansion to ...
-
Over-the-counter COVID-19 testing now available at CVS Pharmacy
CVS Pharmacy, the retail division of CVS Health (NYSE: CVS), today announced the availability of three over-the-counter COVID-19 testing options in stores and online. The tests include the Ellume COVID-19 Home Test, the Abbott BinaxNOW COVID-19 Antigen Self Test and the Pixel by Labcorp PCR Test Home Collection Kit. All three tests have received FDA Emergency Use Authorization (EUA), do not ...
-
Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test.
Kephera Diagnostics has launched a new study aimed at collecting blood samples from volunteers at least 18 years of age who have been confirmed positive for COVID-19, for use in development of an antibody test for the virus. The new test will determine whether symptomatic as well as asymptomatic individuals have been infected with the virus that causes COVID-19 by detecting antibodies to ...
-
Breath analysis to detect COVID-19
Efforts to develop a quick and non-invasive breath test for the presence of COVID-19 are underway in Vancouver, British Columbia. Imspex’s BreathSpec® is one of a battery of tests that are being used by Dr Renelle Myers and her Vancouver Coastal Health team in their work to develop a breath test that identifies the possible presence of COVID-19 in people who are showing minimal symptoms ...
-
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for ...
-
German Federal Ministry of Education and Research („BMBF“) selects tiakis Biotech AG to develop Tiprelestat as a potential therapeutic for COVID-19.
tiakis Biotech AG (formerly Proteo Biotech AG) has announced that the German BMBF has selected the Company to conduct a clinical phase 1b/2 trial to develop its investigational medical product Tiprelestat as a potential therapeutic for COVID-19. The aim of the clinical trial is to assess Tiprelestat’s efficacy to attenuate severe disease progression of COVID-19. The Company expects the ...
-
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population. Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet ...
By Benevolent
-
Alaska Airlines Partners with AZOVA to Provide Ellume COVID-19 Home Tests & Video Observation for Safe, Healthy Travel
AZOVA Inc., creator of the world’s most comprehensive digital health network for COVID-19 testing and vaccination management, and Ellume, the company to bring the first non-prescription over-the-counter COVID-19 home test to market, today announced an official partnership with Alaska Airlines to provide a convenient, at-home rapid testing solution for its passengers. The Ellume COVID-19 ...
-
Nanologica to Participate in Partnering Against COVID-19
Nanologica will participate in the virtual partnering event Partnering Against COVID-19 on May 4 – 6. The aim of the event is to support the fight against COVID-19 and to accelerate global collaboration. Participating parties will consist of organizations working with solutions for COVID-19 testing, treatment and prevention. “In these difficult times, we are excited to take part ...
-
People who have recovered from COVID-19 Can Now Donate their Convalescent Plasma in select Grifols U.S. Plasma Donor Centers
Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines, today announced it has begun identifying, screening and selecting volunteer donors who have recovered from COVID-19 to donate their plasma in select U.S. cities. The plasma will be used to produce ...
-
ExThera Medical & Fresenius Medical Care Sign Distribution Agreement for Seraph 100 Blood Purification Device in Mexico
Seraph 100 used for Blood Purification and Pathogen Reduction in Sepsis and COVID-19 Treatments MARTINEZ, Calif. – ExThera Medical and Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, announced the expanded distribution of ExThera’s Seraph® 100 Microbind® Affinity Blood Filter in Mexico. In 2021, ExThera ...
-
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed resultsfrom the Adaptive COVID-19 Treatment Trial (ACTT-2) published in the New England Journal of Medicine showed that baricitinib in combination with remdesivir reduces recovery time, improves clinical status and demonstrates a trend towards a decrease in mortality in hospitalised COVID-19 patients with pneumonia. Those who took both drugs had a median time to recovery of seven ...
By Benevolent
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you